This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Shire ViroPharma Incorporated
Shire ViroPharma Incorporated, a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has established itself as a leader in developing innovative therapies for rare diseases, particularly in the areas of infectious diseases and gastrointestinal disorders. With a strong focus on research and development, Shire ViroPharma is renowned for its unique product offerings, including treatments that address unmet medical needs. The company has achieved significant milestones, positioning itself as a trusted name in the market. Its commitment to advancing healthcare solutions underscores its reputation for excellence and innovation in the biopharmaceutical sector.
DitchCarbon Score
How does Shire ViroPharma Incorporated's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shire ViroPharma Incorporated's score of 75 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shire ViroPharma Incorporated, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its climate strategy, Shire ViroPharma is aligned with the initiatives and targets set by Takeda Pharmaceutical Company Limited. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions across their operations. However, specific reduction targets or achievements for Shire ViroPharma have not been disclosed. The company is also involved in broader climate initiatives, although details on specific pledges or commitments are not available. As a subsidiary, Shire ViroPharma's climate actions are likely influenced by Takeda's overarching sustainability goals, which focus on reducing emissions and enhancing environmental stewardship. In summary, while Shire ViroPharma does not provide specific emissions data or reduction targets, it is part of a corporate family that is actively engaged in climate commitments through Takeda Pharmaceutical Company Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shire ViroPharma Incorporated is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
